{"id":"W4401385117","doi":"10.1007/s13555-024-01242-9","title":"More Time Spent with Clear Skin and No Itch with Upadacitinib versus Dupilumab for Atopic Dermatitis","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research; SKiN Health; Queen's University","funders":"Janssen Pharmaceuticals; LEO Pharma; Coherus Biosciences; Argenx; Daewoong Pharmaceutical Company; Sanofi Genzyme; Pfizer; Incyte; National Eczema Association; Celldex Therapeutics; Dermira; Sun Pharma; Regeneron Pharmaceuticals; Kiniksa Pharmaceuticals; AbbVie; Sanofi; GlaxoSmithKline; Celgene; Galderma; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Amgen; Castle Biosciences","keywords":"Dupilumab; Atopic dermatitis; Medicine; Dermatology; Placebo; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002076933,0.0006028075,0.001475386,0.0003336673,0.0002558756,0.000590546,0.0003950977,0.0003717087,0.003009254],"category_scores_gemma":[0.002002016,0.0002456431,0.002191272,0.0004092593,0.0003405139,0.0004332788,0.0003040006,0.0006946321,0.0002040657],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004880062,"about_ca_system_score_gemma":0.0006228327,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004907764,"about_ca_topic_score_gemma":0.001106958,"domain_scores_codex":[0.9988626,0.000536466,0.0001103204,0.0002064414,0.0001747161,0.0001094958],"domain_scores_gemma":[0.9982942,0.0008183625,0.0005417626,0.00008540066,0.00007928563,0.0001811029],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8068152,0.003206827,0.08876722,0.002111329,0.0113487,0.00009026761,0.0001353596,0.001802314,0.006702822,0.0001148499,0.001150438,0.07775459],"study_design_scores_gemma":[0.1127486,0.2554199,0.5856919,0.0003143789,0.02751495,0.0006575512,0.0002191228,0.003190324,0.008830337,0.0004548798,0.004859635,0.00009854067],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9946399,0.003566668,0.0002306629,0.00005146392,0.0000406115,0.0002599375,0.0006672886,0.00001381576,0.0005296675],"genre_scores_gemma":[0.9985564,0.0004355722,0.0001658105,0.00006368005,0.00003404467,0.0001924723,0.0003628606,0.000002486095,0.000186634],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003009254,"threshold_uncertainty_score":0.010984,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01093153645027651,"score_gpt":0.2685414857762176,"score_spread":0.2576099493259411,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}